Simian foamy virus cDNA and Antigen

Simian foamy virus (SFV) is a retrovirus that can infect various species of monkeys and apes. SFV encodes for several proteins, including the Group specific antigen, Env protein surface domain, Integrase, Surface protein, Reverse transcriptase, Surface protein, and Transmembrane protein. These proteins are essential for viral replication and pathogenesis, as well as potential targets for antiviral therapies and vaccine development.

The Group specific antigen (Gag) protein is involved in the assembly and maturation of the viral particle, while the Env protein surface domain is responsible for viral entry into host cells. The Integrase protein is involved in the integration of the viral genome into the host cell DNA, while the Reverse transcriptase protein is responsible for the reverse transcription of viral RNA into DNA.

The Surface protein and Transmembrane protein are involved in the binding and fusion of the virus to host cells and are critical for viral pathogenesis. Additionally, these proteins have been studied as potential targets for antiviral therapies and vaccine development.

Understanding the functions of the various SFV proteins is important for developing effective treatments against this virus. For example, the Gag protein has been shown to be an effective target for antiviral therapy, and inhibitors of reverse transcriptase have also been explored as potential therapeutic agents.

The Env protein surface domain is a particularly interesting target for vaccine development, as it is responsible for the initial interaction of the virus with host cells and is the primary target of neutralizing antibodies. Development of a vaccine that elicits a strong immune response against the Env protein could be an effective way to prevent SFV infection.

The Surface and Transmembrane proteins are also potential targets for vaccine development and are being explored for their potential use as immunogens. These proteins have been shown to elicit an immune response in infected individuals, and it is hoped that a vaccine targeting these proteins could provide long-term protection against SFV infection.

The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.